Obstetric antiphospholipid syndrome

References
1 Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4 (02) 295-306
2 Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT. et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002; 46 (04) 1019-1027
3 Schreiber K, Hunt BJ. Pregnancy and antiphospholipid syndrome. Semin Thromb Hemost. 2016; 42 (07) 780-788
4 Meroni PL, Borghi MO, Grossi C, Chighizola CB, Durigutto P, Tedesco F. Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?. Nat Rev Rheumatol. 2018; 14 (07) 433-440
5 Cervera R, Serrano R, Pons-Estel GJ, Ceberio-Hualde L, Shoenfeld Y, de Ramón E. et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015; 74 (06) 1011-1018
6 Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost. 2005; 93 (06) 1147-1152
7 Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N. et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019; 78 (10) 1296-1304
8 Lynch A, Marlar R, Murphy J, Davila G, Santos M, Rutledge J. et al. Antiphospholipid antibodies in predicting adverse pregnancy outcome. A prospective study. Ann Intern Med. 1994; 120 (06) 470-475
9 Abou-Nassar K, Carrier M, Ramsay T, Rodger MA. The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and meta-analysis. Thromb Res. 2011; 128 (01) 77-85
10 Cowchock S, Reece EA. Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Organizing Group of the Antiphospholipid Antibody Treatment Trial. Am J Obstet Gynecol. 1997; 176 (05) 1099-1100
11 Del Ross T, Ruffatti A, Visentin MS, Tonello M, Calligaro A, Favaro M. et al. Treatment of 139 pregnancies in antiphospholipid-positive women not fulfilling criteria for antiphospholipid syndrome: a retrospective study. J Rheumatol. 2013; 40 (04) 425-429
12 Czwalinna A, Bergmann F. Prevention of pregnancy complications in antiphospholipid syndrome. Hamostaseologie. 2020; 40 (02) 174-183
13 Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ. 1997; 314 (7076): 253-257
14 Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol. 2002; 100 (03) 408-413
15 Cohn DM, Goddijn M, Middeldorp S, Korevaar JC, Dawood F, Farquharson RG. Recurrent miscarriage and antiphospholipid antibodies: prognosis of subsequent pregnancy. J Thromb Haemost. 2010; 8 (10) 2208-2213
16 Mak A, Cheung MW, Cheak AA, Ho RC. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology. 2010; 49 (02) 281-288
17 van Hoorn ME, Hague WM, van Pampus MG, Bezemer D, de Vries JI. FRUIT Investigators. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. Eur J Obstet Gynecol Reprod Biol. 2016; 197: 168-173
18 Belizna C, Pregnolato F, Abad S, Alijotas-Reig J, Amital H, Amoura Z. et al. HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. Autoimmun Rev. 2018; 17 (12) 1153-1168
19 Ruffatti A, Tonello M, Visentin MS, Bontadi A, Hoxha A, De Carolis S. et al. Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology. 2011; 50 (09) 1684-1689
20 Fredi M, Andreoli L, Aggogeri E, Bettiga E, Lazzaroni MG, Le Guern V. et al. Risk factors for adverse maternal and fetal outcomes in women with confirmed aPL positivity: results from a multicenter study of 283 pregnancies. Front Immunol. 2018; 9: 864
21 Bramham K, Thomas M, Nelson-Piercy C, Khamashta M, Hunt BJ. First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. Blood. 2011; 117 (25) 6948-6951
22 Tenti S, Cheleschi S, Guidelli GM, Galeazzi M, Fioravanti A. Intravenous immunoglobulins and antiphospholipid syndrome: how, when and why? A review of the literature. Autoimmun Rev. 2016; 15 (03) 226-235
23 Ruffatti A, Favaro M, Hoxha A, Zambon A, Marson P, Del Ross T. et al. Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study. J Reprod Immunol. 2016; 115: 14-19
24 El-Haieg DO, Zanati MF, El-Foual FM. Plasmapheresis and pregnancy outcome in patients with antiphospholipid syndrome. Int J Gynaecol Obstet. 2007; 99 (03) 236-241
25 Mekinian A, Lazzaroni MG, Kuzenko A, Alijotas-Reig J, Ruffatti A, Levy P. et al. The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a European multicenter retrospective study. Autoimmun Rev. 2015; 14 (06) 498-502
26 Ruffatti A, Tonello M, Hoxha A, Sciascia S, Cuadrado MJ, Latino JO. et al. Effect of additional treatments combined with conventional therapies in pregnant patients with high-risk antiphospholipid syndrome: a multicentre study. Thromb Haemost. 2018; 118 (04) 639-646
27 Schreiber K, Breen K, Cohen H, Jacobsen S, Middeldorp S, Pavord S. et al. HYdroxychloroquine to Improve Pregnancy Outcome in Women with AnTIphospholipid Antibodies (HYPATIA) protocol: a multinational randomized controlled trial of hydroxychloroquine versus placebo in addition to standard treatment in pregnant women with antiphospholipid syndrome or antibodies. Semin Thromb Hemost. 2017; 43 (06) 562-571
28 de Jesús GR, Sciascia S, Andrade D, Barbhaiya M, Tektonidou M, Banzato A. et al. Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study. BJOG. 2019; 126 (05) 656-661
29 Silver RM. Catastrophic antiphospholipid syndrome and pregnancy. Semin Perinatol. 2018; 42 (01) 26-32
30 Rodríguez-Pintó I, Moitinho M, Santacreu I, Shoenfeld Y, Erkan D, Espinosa G. et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the International CAPS Registry. Autoimmun Rev. 2016; 15 (12) 1120-1124
31 Berman H, Rodríguez-Pintó I, Cervera R, Morel N, Costedoat-Chalumeau N, Erkan D. et al. Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmune Rev. 2013; 12 (11) 1085-1090
32 Unlu O, Erkan D. Catastrophic antiphospholipid syndrome: candidate therapies for a potentially lethal disease. Annu Rev Med. 2017; 68: 287-296